Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Ltd. (IVZ) vs Koninklijke Philips NV (PHG) Price & Performance

Invesco Ltd.Trade
Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

Invesco Ltd. vs Koninklijke Philips NV — how do they compare? Invesco Ltd. trades at $29.68 (market cap $13.15B), while Koninklijke Philips NV trades at $26.5 (market cap $26.19B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays the higher dividend (3.79%). Which is the better fit depends on your goals.

IVZPHG
Market Cap
$13.15B$26.19B
Sector
FinancialsHealth
52-Week High
$30.30$32.91
52-Week Low
$20.20$24.54
Enterprise Value
$23.39B$32.46B
Dividend Yield
2.9%3.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Ltd.

Invesco (IVZ) trades at $29.57, down 0.2% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported revenue growth to $6.38B in 2025 but posted a net loss of -$281.70M, reflecting margin pressures. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Positive cash flow from operations of $1.53B in 2025 highlights operational strength, while analyst sentiment leans neutral with a consensus price target of $30.64.

The stock presents a cautious opportunity with solid revenue growth and improving cash flows offset by profitability challenges. Near-term catalysts include potential earnings recovery and dividend payments, but risks from competitive pressures and macroeconomic volatility warrant careful monitoring. The current price near the consensus target suggests limited upside without fundamental improvements.

Koninklijke Philips NV

PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.

PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.

Returns comparison

Trailing returns across standard periods

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG